$TVTX
Travere Therapeutics Inc Stock $tvtx

$tvtx Overview Financials Valuation SEC Filings Company Website

2021 Q2 Form 10-Q Financial Statement

#000143853321000034 Filed on July 29, 2021

Income Statement

Concept	2021 Q2	2020 Q2	2020 Q1
Revenue	$54.62M	$48.43M	$47.77M
YoY Change	12.78%	8.33%	20.72%
Cost Of Revenue	$1.651M	$1.494M	$1.370M
YoY Change	10.51%	52.6%	34.71%
Gross Profit	$52.97M	$46.94M	$46.40M
YoY Change	12.85%	7.34%	20.35%
Gross Profit Margin	96.98%	96.92%	97.13%
Selling, General & Admin	$34.97M	$34.97M	$33.14M
YoY Change	-0.02%	-10.26%	1.44%
% of Gross Profit	66.01%	74.51%	71.42%
Research & Development	$51.81M	$30.79M	$30.25M
YoY Change	68.26%	-18.83%	-9.55%
% of Gross Profit	97.81%	65.6%	65.19%
Depreciation & Amortization	$6.624M	$5.850M	$5.656M
YoY Change	13.23%	20.87%	15.41%
% of Gross Profit	12.51%	12.46%	12.19%
Operating Expenses	$86.77M	$65.76M	$62.84M
YoY Change	31.95%	-19.05%	-19.23%
Operating Profit	-$35.32M	-$23.11M	-$15.07M
YoY Change	52.81%	-36.73%	-60.59%
Interest Expense	-$4.852M	-$4.634M	-$4.887M
YoY Change	4.7%	-3.8%	0.45%
% of Operating Profit
Other Income/Expense, Net	-$3.648M	-$2.892M	-$3.101M
YoY Change	26.14%	37.52%	32.07%
Pretax Income	-$38.96M	-$26.00M	-$18.17M
YoY Change	49.84%	-32.69%	-55.22%
Income Tax	$49.00K	$65.00K	-$19.00M
% Of Pretax Income
Net Earnings	-$39.01M	-$26.07M	$808.0K
YoY Change	49.65%	-32.64%	-101.97%
Net Earnings / Revenue	-71.43%	-53.83%	1.69%
Basic Earnings Per Share	-$0.64	-$0.58	$0.02
Diluted Earnings Per Share	-$0.64	-$0.58	$0.02
COMMON SHARES
Basic Shares Outstanding	60.57M shares	44.76M shares	43.12M shares
Diluted Shares Outstanding	60.57M shares	44.76M shares	43.59M shares

Balance Sheet

Concept	2021 Q2	2020 Q2	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$411.5M	$370.3M	$269.9M
YoY Change	11.14%	24.1%	-0.3%
Cash & Equivalents	$83.29M	$237.2M	$67.02M
Short-Term Investments	$328.3M	$133.1M	$202.8M
Other Short-Term Assets	$7.339M	$7.700M	$5.300M
YoY Change	-4.69%	-27.36%	-44.79%
Inventory	$7.409M	$6.286M	$6.593M
Prepaid Expenses
Receivables	$11.90M	$14.10M	$18.10M
Other Receivables	$400.0K	$20.10M	$20.20M
Total Short-Term Assets	$549.8M	$505.6M	$406.6M
YoY Change	8.75%	10.62%	-14.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.72M	$2.930M	$2.617M
YoY Change	300.0%	-2.82%	-12.62%
Goodwill	$936.0K	$936.0K	$936.0K
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$34.36M	$13.90M	$6.803M
YoY Change	147.29%	9.39%	-49.5%
Total Long-Term Assets	$197.0M	$173.1M	$166.4M
YoY Change	13.77%	-9.15%	-13.39%
TOTAL ASSETS
Total Short-Term Assets	$549.8M	$505.6M	$406.6M
Total Long-Term Assets	$197.0M	$173.1M	$166.4M
Total Assets	$746.8M	$678.7M	$573.1M
YoY Change	10.03%	4.81%	-14.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.343M	$10.20M	$9.966M
YoY Change	-18.19%	-18.54%	30.67%
Accrued Expenses	$62.47M	$44.38M	$41.59M
YoY Change	40.75%	-12.22%	-10.79%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$96.98M	$69.93M	$68.09M
YoY Change	38.67%	-22.8%	-34.58%
LONG-TERM LIABILITIES
Long-Term Debt	$220.9M	$210.0M	$207.4M
YoY Change	5.17%	5.05%	5.01%
Other Long-Term Liabilities	$43.73M	$19.51M	$13.31M
YoY Change	124.15%	-11.74%	-43.14%
Total Long-Term Liabilities	$43.73M	$19.51M	$13.31M
YoY Change	124.15%	-11.74%	-43.14%
TOTAL LIABILITIES
Total Short-Term Liabilities	$96.98M	$69.93M	$68.09M
Total Long-Term Liabilities	$43.73M	$19.51M	$13.31M
Total Liabilities	$414.5M	$360.0M	$347.3M
YoY Change	15.11%	-2.82%	-9.07%
SHAREHOLDERS EQUITY
Retained Earnings	-$678.8M	-$441.7M	-$415.6M
YoY Change	53.67%	26.31%	33.65%
Common Stock	$1.012B	$759.0M	$642.9M
YoY Change	33.3%	21.24%	7.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$332.3M	$318.6M	$225.7M
YoY Change
Total Liabilities & Shareholders Equity	$746.8M	$678.7M	$573.1M
YoY Change	10.03%	4.81%	-14.17%

Cashflow Statement

Concept	2021 Q2	2020 Q2	2020 Q1
OPERATING ACTIVITIES
Net Income	-$39.01M	-$26.07M	$808.0K
YoY Change	49.65%	-32.64%	-101.97%
Depreciation, Depletion And Amortization	$6.624M	$5.850M	$5.656M
YoY Change	13.23%	20.87%	15.41%
Cash From Operating Activities	$6.492M	-$6.450M	-$29.16M
YoY Change	-200.65%	-66.25%	42.28%
INVESTING ACTIVITIES
Capital Expenditures	-$4.307M	-$4.440M	$208.0K
YoY Change	-3.0%	30.97%	994.74%
Acquisitions
YoY Change
Other Investing Activities	-$67.50M	$72.23M	$44.17M
YoY Change	-193.45%	152.38%	-694.48%
Cash From Investing Activities	-$71.80M	$67.80M	$39.55M
YoY Change	-205.9%	168.73%	-446.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$108.7M	$100.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	306.0K	108.8M	-$5.773M
YoY Change	-99.72%	-34096.87%	420.09%
NET CHANGE
Cash From Operating Activities	6.492M	-6.450M	-$29.16M
Cash From Investing Activities	-71.80M	67.80M	$39.55M
Cash From Financing Activities	306.0K	108.8M	-$5.773M
Net Change In Cash	-65.01M	170.1M	$4.583M
YoY Change	-138.21%	2833.45%	-113.87%
FREE CASH FLOW
Cash From Operating Activities	$6.492M	-$6.450M	-$29.16M
Capital Expenditures	-$4.307M	-$4.440M	$208.0K
Free Cash Flow	$10.80M	-$2.010M	-$29.36M
YoY Change	-637.26%	-87.21%	43.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001438533
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36257
	dei	Entity Registrant Name EntityRegistrantName	TRAVERE THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-4842691
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3611 Valley Centre Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
	dei	City Area Code CityAreaCode	888
	dei	Local Phone Number LocalPhoneNumber	969-7879
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	TVTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	60717176	shares
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	83288000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84772000	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	439411000	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	276111000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2021Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	439502000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	276817000	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11860000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15925000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	7409000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	7608000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7339000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8143000	USD
CY2021Q2	us-gaap	Income Tax Receivable IncomeTaxReceivable	400000	USD
CY2020Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	17142000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	549798000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	410407000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11720000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9418000	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	34361000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	33489000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	149951000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	153189000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	936000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	936000	USD
CY2021Q2	us-gaap	Assets Assets	746766000	USD
CY2020Q4	us-gaap	Assets Assets	607439000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	8343000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12133000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	62465000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	56793000	USD
CY2021Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	8869000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6334000	USD
CY2021Q2	tvtx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	17300000	USD
CY2020Q4	tvtx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	17400000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	96977000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	92660000	USD
CY2021Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	220861000	USD
CY2020Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	215339000	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	43725000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	40527000	USD
CY2021Q2	tvtx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	52900000	USD
CY2020Q4	tvtx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	47700000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	414463000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	396226000	USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60710876	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60710876	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52248431	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52248431	shares
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2021Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1011692000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	797985000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-678754000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-585875000	USD
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-641000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-902000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	332303000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	211213000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	746766000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	607439000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	54617000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48430000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	102024000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	96199000	USD
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1651000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1494000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3296000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2864000	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51807000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30790000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	99753000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	61038000	USD
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34965000	USD
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34971000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	71743000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	68110000	USD
CY2021Q2	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	1509000	USD
CY2020Q2	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	4286000	USD
	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	10096000	USD
	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	2363000	USD
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	89932000	USD
CY2020Q2	us-gaap	Costs And Expenses CostsAndExpenses	71541000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	184888000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	134375000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-35315000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-23111000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-82864000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-38176000	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	216000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	426000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-877000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	235000	USD
CY2021Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	988000	USD
CY2020Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1316000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1397000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	3291000	USD
CY2021Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4852000	USD
CY2020Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4634000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-10173000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-9521000	USD
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3648000	USD
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2892000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9653000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5995000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-38963000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26003000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-92517000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-44171000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	49000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	362000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18911000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-39012000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-26068000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-92879000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-25260000	USD
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.58
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.58
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.59
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.59
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60571259	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60571259	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44763843	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44763843	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58431770	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58431770	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43943370	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43943370	shares
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-39012000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-26068000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-92879000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-25260000	USD
CY2021Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-227000	USD
CY2020Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-247000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	875000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-56000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-152000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	3146000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-614000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	729000	USD
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39391000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23169000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-92618000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24587000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-92879000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-25260000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12694000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11507000	USD
	tvtx	Noncash Interest Expense NoncashInterestExpense	759000	USD
	tvtx	Noncash Interest Expense NoncashInterestExpense	893000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-660000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-337000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	5522000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	5147000	USD
	tvtx	Provision Benefit For Inventory ProvisionBenefitForInventory	962000	USD
	tvtx	Provision Benefit For Inventory ProvisionBenefitForInventory	662000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	14767000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11474000	USD
	tvtx	Employee Stock Purchase Plan Expense EmployeeStockPurchasePlanExpense	437000	USD
	tvtx	Employee Stock Purchase Plan Expense EmployeeStockPurchasePlanExpense	390000	USD
	tvtx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	10096000	USD
	tvtx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	2363000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-3602000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-8674000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1807000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-274000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4056000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3979000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	764000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	875000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-17011000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	18714000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1224000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2508000	USD
	tvtx	Change In Lease Assets And Liabilities Net ChangeInLeaseAssetsAndLiabilitiesNet	5492000	USD
	tvtx	Change In Lease Assets And Liabilities Net ChangeInLeaseAssetsAndLiabilitiesNet	0	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4681000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-16407000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-453000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-196000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19978000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35608000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4598000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	518000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	8979000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	8532000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	242064000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	153146000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	406000000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	36743000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-177513000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	107353000	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1399000	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	6101000	USD
	tvtx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1050000	USD
	tvtx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1050000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3074000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	431000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1275000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1098000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	196056000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	103022000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-49000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-33000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1484000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	174734000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84772000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62436000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83288000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	237170000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	362689000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	225748000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7288000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5760000	USD
CY2021Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	319000	USD
CY2020Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	371000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-98000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	108644000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-152000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	3146000	USD
CY2021Q2	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-227000	USD
CY2020Q2	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-247000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1496000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1291000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-39012000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-26068000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	332303000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	318645000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	211213000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	221196000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	14767000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11474000	USD
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	3074000	USD
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	431000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	194157000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	108644000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-614000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	729000	USD
	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	875000	USD
	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-56000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1710000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1487000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-92879000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-25260000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	332303000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	318645000	USD
	us-gaap	Nature Of Operations NatureOfOperations	DESCRIPTION OF BUSINESS<div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Travere Therapeutics, Inc. (“we”, “our”, “us”, “Travere” and the “Company”) refers to Travere Therapeutics, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Travere is a fully integrated biopharmaceutical company headquartered in San Diego, California focused on identifying, developing and delivering life-changing therapies to people with rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with serious or rare diseases and that we believe offer attractive growth characteristics. </span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The ongoing novel coronavirus (COVID-19) pandemic has resulted in travel restrictions, quarantines, “stay-at-home” and “shelter-in-place” orders and extended shutdown of certain businesses around the world. While the impact of the COVID-19 pandemic did not have a material adverse effect on our financial position or results of operations for the six months ended June 30, 2021, these governmental actions and similar actions that may be enacted in the future, and the widespread economic disruption arising from the pandemic, have the potential to materially impact our business and influence our business decisions. The extent and duration of the pandemic is unknown, and the future effects on our business are uncertain and difficult to predict. The Company is continuing to monitor the events and circumstances surrounding the COVID-19 pandemic, which may require adjustments to the Company’s estimates and assumptions in the future.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Programs:</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sparsentan</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> also known as RE-021, is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (“ERA”), with in vitro selectivity toward endothelin receptor type A, and a potent angiotensin receptor blocker (“ARB”). Sparsentan is currently being evaluated in two pivotal Phase 3 clinical studies in the following indications:</span></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#4c4c4c;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:15.42pt">Focal segmental glomerulosclerosis ("FSGS")</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is a rare kidney disease characterized by proteinuria where the glomeruli become progressively scarred. FSGS is a leading cause of end-stage renal disease.</span></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#4c4c4c;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:15.42pt">Immunoglobulin A nephropathy ("IgAN")</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is an immune-complex-mediated glomerulonephritis characterized by hematuria, proteinuria, and variable rates of progressive renal failure. IgAN is the most common primary glomerular disease.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pegtibatinase (TVT-058) is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU). Classical HCU is a rare metabolic disorder characterized by elevated levels of plasma homocysteine that can lead to vision, skeletal, circulatory and central nervous system issues. Pegtibatinase (TVT-058) is currently being tested in a Phase 1/2 double blind, randomized, placebo-controlled dose escalation study to assess its safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effects in patients with classical HCU. Pegtibatinase (TVT-058) has been granted Rare Pediatric Disease and Fast Track designations by the FDA, as well as orphan drug designation in the United States and Europe. We acquired pegtibatinase (TVT-058) as part of the November 2020 acquisition of Orphan Technologies Limited.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Chenodal (chenodeoxycholic acid or CDCA) is a naturally occurring bile acid that is approved for the treatment of people with radiolucent stones in the gallbladder. CTX is a rare, progressive and underdiagnosed bile acid synthesis disorder affecting many parts of the body. In January 2020, we randomized the first patients in our Phase 3 RESTORE Study to evaluate the effects of Chenodal in adult and pediatric patients with CTX, and the study enrollment remains open. The pivotal study is intended to support an NDA submission for marketing authorization of Chenodal for CTX in the United States. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Programs:</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is a participant in two Cooperative Research and Development Agreements ("CRADAs"), which form a multi-stakeholder approach to pool resources with leading experts, and incorporate the patient perspective early in the therapeutic identification and development process. We have partnered with the National Institutes of Health’s National Center for Advancing Translational Sciences ("NCATS") and leading patient advocacy organizations, CDG Care and Alagille Syndrome Alliance, aimed at the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome, respectively. There are no treatment options currently approved for these diseases.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Approved products:</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt">Chenodal (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. </span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt">Cholbam® (cholic acid capsules) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</span></div>•Thiola® and Thiola EC® (tiopronin tablets) are approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	54617000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48430000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	102024000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	96199000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	242100000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	406000000.0	USD
CY2021Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	439502000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	276817000	USD
CY2021Q2	tvtx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	328100000	USD
CY2021Q2	tvtx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	215000	USD
CY2021Q2	tvtx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	65000	USD
CY2021Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	328250000	USD
CY2021Q2	tvtx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	111311000	USD
CY2021Q2	tvtx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	6000	USD
CY2021Q2	tvtx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	65000	USD
CY2021Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	111252000	USD
CY2021Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	439411000	USD
CY2021Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	221000	USD
CY2021Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	130000	USD
CY2021Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	439502000	USD
CY2020Q4	tvtx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	271098000	USD
CY2020Q4	tvtx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	724000	USD
CY2020Q4	tvtx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	22000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	271800000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	276111000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	728000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	22000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	276817000	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	282594000	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	130000	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	282594000	USD
CY2019Q2	tvtx	Lessee Operating Lease Aggregate Liability LesseeOperatingLeaseAggregateLiability	49500000	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	130000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	155174000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	22000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	155174000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	22000	USD
CY2021Q2	tvtx	Number Of Operating Leases NumberOfOperatingLeases	1	lease
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	34600000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	34500000	USD
CY2020Q4	us-gaap	Lease Incentive Receivable LeaseIncentiveReceivable	7900000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1842000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6020000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6200000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6386000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6578000	USD
CY2021Q2	tvtx	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	18535000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	45561000	USD
CY2021Q2	us-gaap	Incentive To Lessee IncentiveToLessee	566000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9456000	USD
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	35539000	USD
CY2021Q2	tvtx	Operating Lease Incentive Tenant Improvements OperatingLeaseIncentiveTenantImprovements	6485000	USD
CY2021Q2	tvtx	Straight Line Lease Expense In Excess Of Cash Payments StraightLineLeaseExpenseInExcessOfCashPayments	4638000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24416000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24400000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2623000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	32916000	USD
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	35539000	USD
CY2021Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	2400000	USD
CY2020Q2	tvtx	Reduction Of Operating Lease Expense ReductionOfOperatingLeaseExpense	200000	USD
	tvtx	Reduction Of Operating Lease Expense ReductionOfOperatingLeaseExpense	0	USD
	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	2	business
CY2021Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	234700000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83288000	USD
CY2021Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	439502000	USD
CY2021Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	522790000	USD
CY2021Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	70200000	USD
CY2021Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	70200000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84772000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	276817000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	361589000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	65100000	USD
CY2020Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	65100000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	153189000	USD
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6136000	USD
CY2020Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5285000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12088000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10459000	USD
CY2021Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	234700000	USD
CY2021Q2	tvtx	Government Rebates Payable GovernmentRebatesPayable	11756000	USD
CY2020Q4	tvtx	Government Rebates Payable GovernmentRebatesPayable	10707000	USD
CY2021Q2	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	1500000	USD
	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	10100000	USD
CY2020Q2	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	4300000	USD
	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	2400000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	150000000.0	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	273332000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	264676000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	123381000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	111487000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	149951000	USD
CY2021Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	12656000	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	17912000	USD
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60571259	shares
CY2021Q2	tvtx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	8340000	USD
CY2020Q4	tvtx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	7857000	USD
CY2021Q2	tvtx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	21534000	USD
CY2020Q4	tvtx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	10166000	USD
CY2021Q2	tvtx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	4541000	USD
CY2020Q4	tvtx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	3944000	USD
CY2021Q2	tvtx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	3638000	USD
CY2020Q4	tvtx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	6207000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	62465000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	56793000	USD
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44763843	shares
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.58
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58431770	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60571259	shares
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-39012000	USD
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44763843	shares
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-26068000	USD
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.58
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58431770	shares
	us-gaap	Net Income Loss NetIncomeLoss	-92879000	USD
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.59
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.59
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43943370	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43943370	shares
	us-gaap	Net Income Loss NetIncomeLoss	-25260000	USD
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18072393	shares
CY2020Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17110450	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18026005000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16878538000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6200000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	19.23
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7510000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5954000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15204000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11864000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	400000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18900000	USD
CY2021Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4099000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3219000	USD
CY2021Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3310000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4389000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	7409000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	7608000	USD
CY2021Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3500000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3600000	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11900000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15900000	USD
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares

Files In Submission

Name	View Source	Status
0001438533-21-000034-index-headers.html	Edgar Link	pending
0001438533-21-000034-index.html	Edgar Link	pending
0001438533-21-000034.txt	Edgar Link	pending
0001438533-21-000034-xbrl.zip	Edgar Link	pending
ex06302021311.htm	Edgar Link	pending
ex06302021312.htm	Edgar Link	pending
ex06302021321.htm	Edgar Link	pending
ex06302021322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tvtx-20210630.htm	Edgar Link	pending
tvtx-20210630.xsd	Edgar Link	pending
tvtx-20210630_cal.xml	Edgar Link	unprocessable
tvtx-20210630_def.xml	Edgar Link	unprocessable
tvtx-20210630_g1.gif	Edgar Link	pending
tvtx-20210630_htm.xml	Edgar Link	completed
tvtx-20210630_lab.xml	Edgar Link	unprocessable
tvtx-20210630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVTX
Travere Therapeutics Inc Stock $tvtx

2021 Q2 Form 10-Q Financial Statement

#000143853321000034 Filed on July 29, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX Travere Therapeutics Inc Stock $tvtx

2021 Q2 Form 10-Q Financial Statement

#000143853321000034 Filed on July 29, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX
Travere Therapeutics Inc Stock $tvtx